Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?

Overlapping FDA product approval and Medicare coverage reviews could help biopharmaceutical firms avoid a later Medicare national coverage determination for a new therapy, CMS Coverage and Analysis Group Director Louis Jacques suggested during a webinar sponsored by Avalere Health Sept. 30.